Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.

Autor: Gainullin M; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; NEC OncoImmunity AS, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Federico L; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Røkke Osen J; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Chaban V; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Kared H; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Alirezaylavasani A; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Lund-Johansen F; Department of Immunology, Oslo University Hospital, Oslo, Norway.; ImmunoLingo Convergence Center, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Wildendahl G; Agency for Social and Welfare Services, Oslo, Norway., Jacobsen JA; Agency for Social and Welfare Services, Oslo, Norway., Sarwar Anjum H; Agency for Social and Welfare Services, Oslo, Norway., Stratford R; NEC OncoImmunity AS, Oslo, Norway., Tennøe S; NEC OncoImmunity AS, Oslo, Norway., Malone B; NEC OncoImmunity AS, Oslo, Norway., Clancy T; NEC OncoImmunity AS, Oslo, Norway., Vaage JT; Department of Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Henriksen K; Agency for Social and Welfare Services, Oslo, Norway.; Student Health Services, University of Oslo, Oslo, Norway., Wüsthoff L; Unit for Clinical Research on Addictions, Oslo University Hospital, Oslo, Norway.; Norwegian Centre for Addiction Reasearch, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Munthe LA; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Jan 17; Vol. 14, pp. 1235210. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2023).